港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Prosperous Printing Company Limited 萬 里 印 刷 有 限 公 司 訂立優惠券服務合作備忘錄 本 公 佈 由 萬 里 印 刷 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 本 公 司 股 東（「股 東」）及 有 意 投 資 者 提 供 本 集 團 的 最 新 業 務 發 展 更 新 資 料。 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 宣 佈，於2026年3月23日（交 易 時 段 後），Jade View Limited（「Jade View」）與 米 索 飛（香 港）有 限 公 司（「米索飛」）（統 稱「訂約方」）訂 立 優 惠 券 服 務 合 作 備 忘 錄（「備忘錄」）。根 據 ...

Summary of Collegium Pharmaceutical Investor Call Company Overview - **Company**: Collegium Pharmaceutical (NasdaqGS:COLL) - **Event**: Investor Call regarding the acquisition of AZSTARYS from Corium Therapeutics - **Date**: March 19, 2026 Key Points Acquisition Details - Collegium announced the acquisition of AZSTARYS and relevant subsidiaries from Corium Therapeutics for **$650 million** in cash, with potential contingent payments of up to **$135 million** based on sales and regulatory milestones [8][10][19] - The acquisition is expected to close in the **second quarter of 2026** [19] Strategic Rationale - The acquisition significantly expands Collegium's position in the **ADHD** market, adding a second differentiated treatment alongside **Jornay PM** [5][19] - AZSTARYS is expected to extend ADHD revenues into **2037**, five years beyond Jornay PM's expected loss of exclusivity [7][19] - The deal is aligned with Collegium's capital allocation strategy, balancing portfolio expansion and fiscal responsibility [8][19] Financial Impact - The acquisition is projected to be immediately accretive to adjusted EBITDA, with AZSTARYS expected to generate over **$50 million** in pro forma net revenues in the second half of **2026** [10][11] - Collegium generated over **$329 million** in cash from operations in **2025**, indicating strong cash flow to support the acquisition [9] Market Context - The ADHD market is large and growing, with approximately **22 million** patients in the U.S. and **111 million** prescriptions written in **2025** [12] - ADHD prescriptions have been growing at about **8% annually** over the past five years, with **90%** of prescriptions for stimulant medications [12] Product Differentiation - Jornay PM is unique as it is taken at night and provides efficacy upon awakening, while AZSTARYS combines fast and long-acting medications in one capsule [15][17] - Both products target different patient needs, with Jornay PM primarily used in children and adolescents, and AZSTARYS having a more balanced distribution between adults and children [17][18] Sales and Marketing Strategy - Collegium plans to leverage its existing ADHD commercial infrastructure to drive growth for both products, expecting significant cost synergies of over **$50 million** within 12 months post-acquisition [10][19] - The company has a sales force of **180 representatives**, compared to Corium's **100**, which will enhance marketing efforts for AZSTARYS [30][37] Future Outlook - Collegium remains open to further acquisitions in both ADHD and potentially other therapeutic areas, maintaining a focus on capital-efficient opportunities [50][51] - The company aims to maximize the potential of both Jornay PM and AZSTARYS, ensuring broad access and support for the ADHD community [45][54] Additional Insights - Healthcare professionals have rated both Jornay PM and AZSTARYS highly, with **70%** indicating a strong intent to increase prescribing of Jornay PM and **53%** for AZSTARYS [15][16] - The acquisition reflects Collegium's commitment to innovation and financial discipline, aiming to create long-term shareholder value [19][21] Conclusion - The acquisition of AZSTARYS is a strategic move for Collegium, enhancing its ADHD portfolio and positioning the company for sustained growth and shareholder value creation in the biopharmaceutical sector [21][64]

Group 1 - The core viewpoint of the news is that Shenkai Co., Ltd. (SZ002633) experienced a limit-up in stock price due to strategic transformation, state-owned capital involvement, and business expansion [1] Group 2 - The company is undergoing a strategic transformation by establishing multiple subsidiaries in new fields such as power equipment, gas turbines, and deep-sea wind power, which broadens its business scope [1] - The establishment of the Taierzhuang State-owned Assets Supervision and Administration Commission as the new actual controller provides more stable shareholder support and resources, which is beneficial for the company's long-term development [1] - The company has set up a research and development headquarters in Shanghai focusing on "bottleneck" technologies to enhance core competitiveness, and has established branches in Shenzhen and Shandong to optimize production capacity and market responsiveness [1] Group 3 - Shenkai Co., Ltd. has played a role in the underwater robotics supply chain by providing components for deep-sea equipment such as the "Deep Sea Warrior," indicating potential for business expansion [1] - Recent data from Tonghuashun shows that some stocks in the machinery manufacturing sector have been active, indicating increased market attention towards the sector where Shenkai Co., Ltd. is located [1] - From a technical perspective, if the MACD indicator forms a golden cross and short-term moving averages show a bullish arrangement, it may attract more capital inflow, contributing to the stock price increase [1]

Core Insights - The company is actively seeking key breakthroughs outside the Yangtze River Delta and has increased its recruitment efforts, expanding its sales team to over 600 members [2] - The company is optimizing its distributor structure and will provide specific changes and regional revenue proportions in its upcoming periodic report [2] - The company is implementing process reengineering focused on business growth, enhancing operational efficiency and market responsiveness through management, organizational, and mechanism changes [2] - The company is strengthening dynamic budget management and ensuring marketing expenses yield efficiency in core products and effective channels through detailed accounting [2] - The company continues to optimize its product structure to improve profit margins [2]

Core Viewpoint - The company is focusing on its core business of industrial brakes while leveraging its technological advantages to explore new application areas [1] Group 1: Business Strategy - The company is actively expanding into new application fields, particularly in oil extraction equipment, which requires high safety and reliability standards for braking systems [1] - This strategic focus aligns well with the company's technological strengths, making it a key area for future development [1] Group 2: Long-term Development - The cultivation of new business areas is expected to provide new momentum for the company's medium to long-term growth [1] - Expanding product categories will enhance the company's profitability [1]

Group 1 - The core viewpoint of the article is that Aide New Energy has announced the acquisition of equity in an Australian gold mining company, marking its entry into the gold mining sector [1] - On January 29, Aide New Energy announced a rights issue, offering one share for every two existing shares held, totaling 175 million shares at a subscription price of HKD 2.88 per share, aiming to raise approximately HKD 504 million [1] - The net proceeds from the rights issue, estimated at around HKD 503 million, will be used to identify suitable acquisition targets and investment opportunities, as well as to supplement the group's working capital [1] Group 2 - The acquisition of the Australian gold mining company is a significant step for Aide New Energy in utilizing the funds raised from the rights issue, further diversifying its business portfolio [1] - The rights issue shares, once issued and fully paid, will rank equally with the existing issued shares, and the controlling shareholder Prominence Investment and executive director Wu Haikan will subscribe for their respective shares [1]

Business Progress - The subsidiary Guangzhou Taihe Oncology Hospital has been approved to enter the "Hong Kong and Macau Drug and Device Access" list in the Guangdong-Hong Kong-Macao Greater Bay Area, allowing the introduction of innovative oncology drugs and devices that are already approved in Hong Kong and Macau but not yet in mainland China, potentially expanding business boundaries and strengthening competitive advantages [2] Executive Changes - On January 12, 2026, the company announced that Jiang Wei has taken over as president, which may influence the future strategic execution direction [3] Financial Performance - The latest financial report indicates that for the first half of 2025, the company achieved revenue of approximately 200 million, with losses narrowing by 2.9% year-on-year, although revenue decreased by 8.3% year-on-year. The operational commencement of the proton therapy center has improved the hospital business's gross margin, necessitating attention to the sustainability of future profitability [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Dufu Liquor Group Limited 杜甫酒業集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：986） 自願公告－業務發展最近情況 杜甫酒業集團有限公司（「本公司」，連其附屬公司統稱「本集團」）董事（「董事」 會（「董事會」）自願作出。 服務合約 本公司董事會欣然宣佈，本公司已與徐國強先生（以下簡稱「徐先生」）訂立服務合 約（「服務合約」）。基於本服務合同，雙方將發揮各自優勢，與及對本公司務業拓 展及實行提供具體規劃。 服務內容 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 中國環保能源投資有限公司* 承董事會命 杜甫酒業集團有限公司 聯席主席兼執行董事 網路應用科技及顧問服務 網路系統保安服務 徐先生，於二零爾三年於國家開放大學獲得行動互聯應用技術專業證書。現在是福州 市閩清縣鑫恆強勞務有限公司/總經理，主持公司內整體工作，制定公司經營方針、 目標、計畫等。 訂立服務 ...

Financial Performance - In the first three quarters of 2025, the total operating revenue of Cixing Co., Ltd. was 1.489 billion yuan, a year-on-year decrease of 16.54% [2] - The net profit attributable to the parent company was 122 million yuan, down 60.71% year-on-year [2] - The gross profit margin was 31.10%, and the net profit margin was 8.15%, but the operating cash flow per share was negative, indicating short-term operational pressure [2] Stock Performance - In February 2026, Cixing's stock price experienced significant fluctuations, with a drop of 2.06% on February 5 and a net outflow of 8.4664 million yuan in main funds [3] - On February 9, the stock price rose by 2.23%, closing at 7.35 yuan per share, with a net inflow of 3.4220 million yuan in main funds, bringing the total market value to approximately 5.884 billion yuan [3] - Year-to-date, the stock price has increased by 3.96%, but there has been a decline of 4.30% over the past 60 days, indicating mixed market sentiment [3] Recent Events - In May 2025, Cixing announced plans to acquire the defense technology company Shenyang Shunyi Technology Co., Ltd., but the transaction was terminated in August 2025 [4] - In January 2026, Beifang Changlong announced plans to cash purchase 51% of Shunyi Technology, mentioning that Cixing might participate, but the transaction is still in the intention stage and specific terms are pending negotiation [4] Company Status - In December 2025, the company showcased new technology products, such as upgraded computer flat knitting machines, at the Shanghai International Textile Industry Exhibition, aiming to expand into non-apparel application scenarios [5] - The company faces risks related to high accounts receivable and cash flow pressure, with accounts receivable accounting for 86.93% of the net profit attributable to the parent company as of the third quarter report [5]

Group 1 - The company Zhejiang Yingte Technology (301399) plans to invest 30 million yuan to establish a wholly-owned subsidiary, Zhejiang Yingruit Enterprise Management Co., Ltd. in Hangzhou [1] - This move may involve business expansion or management optimization, indicating the company's strategic layout direction [1]